Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi, Quentin M. Anstee, M. Marietti, et al.
Nature Reviews Gastroenterology & Hepatology (2017) Vol. 15, Iss. 1, pp. 11-20
Closed Access | Times Cited: 4445

Showing 26-50 of 4445 citing articles:

Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss
Sjaak Pouwels, Nasser Sakran, Yitka Graham, et al.
BMC Endocrine Disorders (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 533
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 19, Iss. 1, pp. 60-78
Open Access | Times Cited: 522
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Robert F. Schwabe, Ira Tabas, Utpal B. Pajvani
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1913-1928
Open Access | Times Cited: 485
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 478
Comparison of MAFLD and NAFLD diagnostic criteria in real world
Su Lin, Jiaofeng Huang, Ming-Fang Wang, et al.
Liver International (2020) Vol. 40, Iss. 9, pp. 2082-2089
Closed Access | Times Cited: 476
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 471
Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
Feng Zhou, Jianghua Zhou, Wenxin Wang, et al.
Hepatology (2019) Vol. 70, Iss. 4, pp. 1119-1133
Closed Access | Times Cited: 458
Epidemiology of chronic liver diseases in the USA in the past three decades
Zobair M. Younossi, Maria Stepanova, Youssef Younossi, et al.
Gut (2019) Vol. 69, Iss. 3, pp. 564-568
Closed Access | Times Cited: 451
The role of the microbiome in NAFLD and NASH
Aleksandra A. Kolodziejczyk, Danping Zheng, Oren Shibolet, et al.
EMBO Molecular Medicine (2018) Vol. 11, Iss. 2
Open Access | Times Cited: 443
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 440
Global liver disease burdens and research trends: Analysis from a Chinese perspective
Jia Xiao, Fei Wang, Nai-Kei Wong, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 1, pp. 212-221
Open Access | Times Cited: 437
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
Shiv Kumar Sarin, Manoj Kumar, Mohammed Eslam, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 5, Iss. 2, pp. 167-228
Open Access | Times Cited: 430
Epidemiology of non-alcoholic and alcoholic fatty liver diseases
Souveek Mitra, Arka De, Abhijit Chowdhury
Translational Gastroenterology and Hepatology (2020) Vol. 5, pp. 16-16
Open Access | Times Cited: 417
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Norbert Stefan, Andreas L. Birkenfeld, Matthias B. Schulze
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 3, pp. 135-149
Open Access | Times Cited: 414
Bile Acids Activated Receptors Regulate Innate Immunity
Stefano Fiorucci, Michele Biagioli, Angela Zampella, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 412
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 396
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 378
Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future
Ana Ruth Araújo, Natalia Rosso, Giorgio Bedogni, et al.
Liver International (2018) Vol. 38, Iss. S1, pp. 47-51
Open Access | Times Cited: 374
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Sakura Yamamura, Mohammed Eslam, Takumi Kawaguchi, et al.
Liver International (2020) Vol. 40, Iss. 12, pp. 3018-3030
Open Access | Times Cited: 365
Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity
Ann Hammarstedt, Silvia Gogg, Shahram Hedjazifar, et al.
Physiological Reviews (2018) Vol. 98, Iss. 4, pp. 1911-1941
Open Access | Times Cited: 361
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Zobair M. Younossi, Mary E. Rinella, Arun J. Sanyal, et al.
Hepatology (2020) Vol. 73, Iss. 3, pp. 1194-1198
Closed Access | Times Cited: 358
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Ferenc E. Mózes, Jenny Lee, Emmanuel Selvaraj, et al.
Gut (2021) Vol. 71, Iss. 5, pp. 1006-1019
Open Access | Times Cited: 357
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
Zobair M. Younossi, Giulio Marchesini, Helena Pinto-Cortez, et al.
Transplantation (2018) Vol. 103, Iss. 1, pp. 22-27
Open Access | Times Cited: 352
NAFLD as a driver of chronic kidney disease
Christopher D. Byrne, Giovanni Targher
Journal of Hepatology (2020) Vol. 72, Iss. 4, pp. 785-801
Open Access | Times Cited: 345
Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 334

Scroll to top